Methasan

Methadone Hydrochloride, the active ingredient in Methasan, is a synthetic opioid agonist presented as an oral formulation for oral use. It is employed in the management of opioid dependence and chronic pain, typically in adult patients under specialist supervision.

GNH USA supplies Methasan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methadone Hydrochloride is used in the opioid pathway to treat dependence and severe pain. - Opioid dependence: reduces withdrawal symptoms and cravings during maintenance therapy. - Chronic pain management: provides long‑acting analgesia for severe, persistent pain. - Opioid detoxification: facilitates medically supervised transition to abstinence.

Methadone Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Drowsiness: sedation, especially during dose initiation. - Nausea or vomiting: gastrointestinal upset. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, potentially life‑threatening. - Cardiac arrhythmias: QT interval prolongation leading to torsades de pointes. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis.

Methadone Hydrochloride requires careful monitoring due to its potency and pharmacologic profile. - Assess cardiac risk: obtain baseline ECG to evaluate QT interval. - Monitor for respiratory depression: especially in opioid‑naïve patients or when combined with CNS depressants. - Adjust dose in hepatic impairment: liver dysfunction may increase plasma levels. - Counsel on pregnancy risks: discuss potential neonatal withdrawal and limited data. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Methadone Hydrochloride interacts with several drug classes that can alter its safety or efficacy.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase methadone plasma concentrations. - QT‑prolonging agents (e.g., haloperidol, quinidine): heighten risk of cardiac arrhythmias. - CNS depressants (e.g., benzodiazepines, barbiturates): amplify respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2B6 inducers (e.g., rifampin, carbamazepine): may reduce methadone levels. - Antidepressants (e.g., SSRIs, SNRIs): can affect serotonin balance and sedation. - Alcohol: additive CNS depression, requires dose adjustment.